Merck KGaA says it'll consider 'larger-scale' acquisitions from 2023 onward

Merck KGaA has been investing heavily in its biopharma business as part of an effort to grow to 25 billion euros in global revenues by 2025. Starting next year, its expansion campaign could include M&A.